Why Opiant Pharmaceuticals Shares Are Soaring Today

  • Opiant Pharmaceuticals Inc OPNT announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overdose.
  • This crossover study conducted in healthy volunteers compared 3 mg nasal nalmefene hydrochloride with 4 mg nasal naloxone hydrochloride in reversing respiratory depression produced by remifentanil, a synthetic opioid. 
  • The two study drugs were assessed by measuring changes in minute ventilation following administration of the respective study drug, with the primary endpoint at five minutes post-administration.
  • Related: Opiant's Multi-Dose Nasal Nalmefene Shows Safety, Tolerability In Opioid Overdose.
  • A preliminary analysis of the 50 subjects completing the study found that treatment with OPNT003 produced nearly twice the reversal of respiratory depression than produced by nasal naloxone at five minutes. 
  • The increases in minute ventilation were 5.745 L/min and 3.011 L/min, with nalmefene and naloxone, respectively. 
  • OPNT003 met the primary endpoint of non-inferiority to nasal naloxone.
  • OPNT003, nasal nalmefene, is developed using a 505(b)(2) pathway. The Company expects to complete the U.S. marketing application filing in 2H of 2022.
  • Price Action: OPNT shares closed 14.8% higher at $22.14 during premarket trading on the last check Thursday.
Posted In: Briefswhy it's movingBiotechNewsHealth CareMoversTrading IdeasGeneral